Biomarin
BioMarin develops and commercialises innovative biopharmaceuticals for rare diseases driven by genetic causes.
Financial Data
-
31st Dec 20 Source: CRO
- €1.1 billion turnover
-
€92.2 million
profit - 468 employees
-
31st Dec 19 Source: CRO
- €1 billion turnover
-
€42 million
profit - 434 employees
- 5 more years available »
Ranking
By Turnover
(€1.1 billion)- 84th in Top Companies
- 14th in Health
By Employees
(468)- 381st in Top Companies
- 58th in Health
- 468
- €1.1 billion
Employees
- Michael O’Donnell CEO/Managing Director
Latest News
- 2:02am Nama clashes with Fingal council over lands with space for up to 7,000 new homes
- May 20 Attempt by investors to appoint inspector to firm ‘without precedent’, court hears
- May 20 Amarenco and SSE among groups to win green Eirgrid contracts
- May 20 Cerberus collected €113m last year from Irish loans it bought after the 2008 crash
- May 20 European shares finish difficult week with a gain